US drug pricing landscape tops 2023 ophthalmic business news
Click Here to Manage Email Alerts
Healio’s top ophthalmic business-related items in 2023 covered the changing landscape of determining prices for drugs in the U.S. and the recall of generic artificial tears.
Check out the year’s top ophthalmic business items below.
Image: Adobe Stock
BLOG: The ‘would you rather’ rule for drug pricing
Historically in the United States, Medicare has not had the legal authority to negotiate the prices of drugs. Essentially, drug prices were unregulated. Read more.
BLOG: Sometimes brand matters: FDA forces recall of 27 generic artificial tears
Oh my. Another FDA recall of generic artificial tears hit the news during eyeball month. Read more.
Bausch + Lomb launches enVista Aspire monofocal, toric IOLs
Bausch + Lomb launched the enVista Aspire monofocal and toric IOLs with intermediate optimized optics in the U.S. Read more.
Bausch + Lomb to acquire Xiidra, ‘front of eye’ assets from Novartis
Novartis has entered a transaction of up to $2.5 billion to divest “front of eye” ophthalmology assets, including Xiidra, to Bausch + Lomb. Read more.
VIDEO: Johnson & Johnson Vision shares data at Hawaiian Eye
In this Healio Video Perspective, Rajesh K. Rajpal, MD, chief medical officer for Johnson & Johnson Vision, discusses the opportunities the company has for learning and sharing information at Hawaiian Eye 2023. Watch here.
Collapse
Healio Coverage
Read more about
Click Here to Manage Email Alerts